On April 11, 2013 Pharmascience Inc. and Université de Montréal reported the signing of an agreement which formalizes and brings to the next level of activity a collaboration that demonstrates the value of academic research, public institutions, patient disease groups and the pharmaceutical industry working together to bring new hope to patients (Press release, Université de Montréal, APR 11, 2013, View Source [SID1234626501]). The agreement was coordinated by the university’s Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The result could be a new use for an old drug, and new hope for people with certain types of acute myeloid leukemia (AML), a blood cancer which today has very few treatment options and only a 10 per cent five-year survival rate. It is a story that demonstrates very clearly the benefits a multi-faceted biopharmaceutical cluster such as the one which exists in Greater Montreal can bring together to make a very complex undertaking possible.
It starts with Dr. Katherine Borden, a Montreal-born research scientist who, after 20 years of education and research in the United States and United Kingdom, was enticed by the Montreal research environment to return in 2004 as the Canada Research Chair in the Molecular Biology of the Cell Nucleus. She is a Professor in the Department of Pathology and Cell Biology in the Faculty of Medicine at Université de Montréal, as well as a Principal Investigator for the university’s Institute for Research in Immunology and Cancer (IRIC).